About IVOSIDENIB
Class: | Antineoplastic agent, IDH1 inhibitor
Use: | Treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a specific IDH1 mutation
Adult dose: | 500 mg orally once daily; may be reduced to 250 mg once daily based on tolerability
Pediatric dose: | Safety and efficacy not established in pediatric patients
Side effects: | Nausea, diarrhea, fatigue, vomiting, abdominal pain, and elevated liver enzymes
Contraindications: | Hypersensitivity to ivosidenib
Drug Class
Antineoplastic agent, IDH1 inhibitor
Uses & Indications
Treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a specific IDH1 mutation
Storage Requirements
Store at 20°C to 25°C (68°F to 77°F); protect from moisture
Manufacturer & Packaging
Manufacturer: AGIOS PHARMACEUTICALS INC., United States of America
Package Size
60'S
Price & Supplier
Price in UAE: AED 151917.00
Dosage Information
Adult Dose
500 mg orally once daily; may be reduced to 250 mg once daily based on tolerability
Pediatric Dose
Safety and efficacy not established in pediatric patients
Side Effects
Nausea, diarrhea, fatigue, vomiting, abdominal pain, and elevated liver enzymes
Contraindications & Precautions
Hypersensitivity to ivosidenib or any component of the formulation; pregnancy
Important Warnings
Risk of differentiation syndrome; monitor for signs and symptoms; liver function tests should be performed prior to and during treatment; potential for QT prolongation; avoid use in pregnancy due to potential harm to the fetus
Related Medicines in Same Category
See also: Other Antineoplastic agent, IDH1 inhibitor medicines available in UAE pharmacies
Vorasidenib
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice.
Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication.
The information presented here is specific to medicines available in UAE pharmacies and is regularly updated
to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.